These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 14765356)
1. Serologic response and antibody-titer decay in adults with pertussis. Heininger U; Cherry JD; Stehr K Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356 [TBL] [Abstract][Full Text] [Related]
2. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. Le T; Cherry JD; Chang SJ; Knoll MD; Lee ML; Barenkamp S; Bernstein D; Edelman R; Edwards KM; Greenberg D; Keitel W; Treanor J; Ward JI; J Infect Dis; 2004 Aug; 190(3):535-44. PubMed ID: 15243929 [TBL] [Abstract][Full Text] [Related]
3. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough. Winsnes R; Lønnes T; Møgster B; Berdal BP Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124 [TBL] [Abstract][Full Text] [Related]
4. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Ward JI; Cherry JD; Chang SJ; Partridge S; Keitel W; Edwards K; Lee M; Treanor J; Greenberg DP; Barenkamp S; Bernstein DI; Edelman R; Clin Infect Dis; 2006 Jul; 43(2):151-7. PubMed ID: 16779740 [TBL] [Abstract][Full Text] [Related]
5. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection. Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126 [TBL] [Abstract][Full Text] [Related]
6. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Cherry JD; Chang SJ; Klein D; Lee M; Barenkamp S; Bernstein D; Edelman R; Decker MD; Greenberg DP; Keitel W; Treanor J; Ward JI Clin Infect Dis; 2004 Dec; 39(11):1715-8. PubMed ID: 15578376 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597 [TBL] [Abstract][Full Text] [Related]
9. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Cherry JD; Xing DX; Newland P; Patel K; Heininger U; Corbel MJ Clin Infect Dis; 2004 Feb; 38(4):502-7. PubMed ID: 14765342 [TBL] [Abstract][Full Text] [Related]
10. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484 [TBL] [Abstract][Full Text] [Related]
11. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. Hallander HO; Ljungman M; Storsaeter J; Gustafsson L APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530 [TBL] [Abstract][Full Text] [Related]
12. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085 [TBL] [Abstract][Full Text] [Related]
13. Antibody Specificity Following a Recent Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T Front Immunol; 2019; 10():1364. PubMed ID: 31275314 [No Abstract] [Full Text] [Related]
14. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589 [TBL] [Abstract][Full Text] [Related]
15. [Acellular pertussis vaccine]. Wiedermann G; Ambrosch F; Vanura H Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820 [TBL] [Abstract][Full Text] [Related]
16. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Tapiainen T; Cherry JD; Heininger U Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771 [TBL] [Abstract][Full Text] [Related]
17. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763 [TBL] [Abstract][Full Text] [Related]
18. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. Thomas MG; Ashworth LA; Miller E; Lambert HP J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651 [TBL] [Abstract][Full Text] [Related]
19. Bordetella parapertussis infections. Mastrantonio P; Giuliano M; Stefanelli P; Sofia T; De Marzi L; Tarabini G; Quarto M; Moiraghi A Dev Biol Stand; 1997; 89():255-9. PubMed ID: 9272358 [TBL] [Abstract][Full Text] [Related]